<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39382830</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Delphi Panel Consensus Statement Generation: COVID-19 Vaccination Recommendations for Immunocompromised Populations in the European Union.</ArticleTitle><Pagination><StartPage>2227</StartPage><EndPage>2253</EndPage><MedlinePgn>2227-2253</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01051-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented pressure on healthcare systems globally. The lack of quality guidelines on the management of COVID-19 in rheumatologic disease, renal disease, hematological malignancy, and solid organ transplant recipients has resulted in a wide variation in clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a Delphi process, a panel of 16 key opinion leaders developed clinical practice statements regarding vaccine recommendations in areas where standards are absent or limited. Agreement among practicing physicians with consensus statements was also assessed via an online physician survey. The strength of the consensus was determined by the following rating system: a strong rating was defined as all four key opinion leaders (KOLs) rating the statement ≥ 8, a moderate rating was defined as three out of four KOLs rating the statement ≥ 8, and no consensus was defined as less than three out of four KOLs provided a rating of ≤ 8. Specialists voted on agreement with each consensus statement for their disease area using the same ten-point scoring system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Key opinion leaders in rheumatology, nephrology, and hematology achieved consensuses for all nine statements pertaining to the primary and booster series with transplant physicians reaching consensus on eight of nine statements. Experts agreed that COVID-19 vaccines are safe, effective, and well tolerated by patients with rheumatological conditions, renal disease, hematologic malignancy, and recipients of solid organ transplants. The Delphi process yielded strong to moderate suggestions for the use of COVID-19 messenger ribonucleic acid (mRNA) vaccines and the necessity of the COVID-19 booster for the immunocompromised population. The expert panel had mixed feelings concerning the measurement of antibody titers, higher-dose mRNA vaccines, and the development of disease-specific COVID-19 guidance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results confirmed the necessity of COVID-19 vaccines and boosters in immunocompromised patients with rheumatologic disease, renal disease, hematological malignancy, and solid organ transplant recipients. Statements where consensus was not achieved were due to absent or limited evidence.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paranilam</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcioni</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pediatric Onco-Hematology with Bone Marrow Transplantation, Azienda Ospedaliera Di Perugia, Piazza Menghini 1, 06132, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Dr Balmis, 03010, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kira Zhi Hua</ForeName><Initials>KZH</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimball-Carroll</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4229-695X</Identifier><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland. samantha.kimball@iconplc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>7700053394</GrantID><Agency>Moderna</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Hematological malignancy</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Renal disease</Keyword><Keyword MajorTopicYN="N">Rheumatologic disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">Solid organ transplant</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Kira Zhi Hua Lai, Jaya Paranilam, Joseph Brown, and Samantha Kimball-Carroll are employed by ICON Plc and have previously worked with Moderna Inc. Francesco Arcioni and Antonio Franco have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39382830</ArticleId><ArticleId IdType="pmc">PMC11499477</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01051-9</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01051-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470707</ArticleId><ArticleId IdType="pubmed">33035991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lievre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer. 2020;141:62–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543792</ArticleId><ArticleId IdType="pubmed">33129039</ArticleId></ArticleIdList></Reference><Reference><Citation>de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel F, et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540213</ArticleId><ArticleId IdType="pubmed">33161241</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467090</ArticleId><ArticleId IdType="pubmed">32971510</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transpl. 2021;21(3):1295–303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753418</ArticleId><ArticleId IdType="pubmed">33259686</ArticleId></ArticleIdList></Reference><Reference><Citation>Couchoud C, Bayer F, Ayav C, Bechade C, Brunet P, Chantrel F, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int. 2020;98(6):1519–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445552</ArticleId><ArticleId IdType="pubmed">32858081</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transpl Rev (Orlando). 2021;35(1): 100588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666542</ArticleId><ArticleId IdType="pubmed">33246166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Qiu X, Wang C, Zhao J, Jiang X, Niu W, et al. Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. Int J Cancer. 2021;148(2):363–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404763</ArticleId><ArticleId IdType="pubmed">32683687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transpl. 2020;35(11):1973–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665620</ArticleId><ArticleId IdType="pubmed">33151337</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium FRSSSCI C. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712850</ArticleId><ArticleId IdType="pubmed">33268442</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al. Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA. 2022;328(14):1427–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513709</ArticleId><ArticleId IdType="pubmed">36156706</ArticleId></ArticleIdList></Reference><Reference><Citation>Open SC, Parker EPK, Horne EMF, Hulme WJ, Tazare J, Zheng B, et al. Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study. Lancet Reg Health Eur. 2023;30: 100636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10155829</ArticleId><ArticleId IdType="pubmed">37363796</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabi Nejad MM, Shobeiri P, Dehghanbanadaki H, Tabary M, Aryannejad A, Haji Ghadery A, et al. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis. Virol J. 2022;19(1):132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358061</ArticleId><ArticleId IdType="pubmed">35941646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojadadi MS, Javadinia SA, Attarian F, Samami E, Sobhani M. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. Front Public Health. 2022;10: 960598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878157</ArticleId><ArticleId IdType="pubmed">36711369</ArticleId></ArticleIdList></Reference><Reference><Citation>Benning L, Morath C, Bartenschlager M, Kim H, Reineke M, Beimler J, et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant. 2022;22(7):1873–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111366</ArticleId><ArticleId IdType="pubmed">35384272</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8568092</ArticleId><ArticleId IdType="pubmed">34735426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mues KE, Kirk B, Patel DA, Gelman A, Chavers LS, Talarico CA, et al. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. Vaccine. 2022;40(47):6730–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9507810</ArticleId><ArticleId IdType="pubmed">36163093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023;14:1204831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10523015</ArticleId><ArticleId IdType="pubmed">37771594</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol. 2022;74(5):e21–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082483</ArticleId><ArticleId IdType="pubmed">35474640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti M, Rinaldi M, Bussini L, Bonazzetti C, Pascale R, Pasquini Z, et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(8):1057–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8916831</ArticleId><ArticleId IdType="pubmed">35289294</ArticleId></ArticleIdList></Reference><Reference><Citation>Overvad M, Koch A, Jespersen B, Gustafsson F, Krause TG, Hansen CH, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study. Am J Transpl. 2022;22(11):2627–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349987</ArticleId><ArticleId IdType="pubmed">35801493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022;12(7): e060425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9251904</ArticleId><ArticleId IdType="pubmed">35777878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, et al. The RECOVAC Immune-response Study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942603</ArticleId><ArticleId IdType="pubmed">34753894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, Haji Ghadery A, Shabani M, Tabary M, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8840778</ArticleId><ArticleId IdType="pubmed">35151362</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis. 2022;74(9):1515–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436392</ArticleId><ArticleId IdType="pubmed">34358310</ArticleId></ArticleIdList></Reference><Reference><Citation>Au WY, Cheung PP. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724446</ArticleId><ArticleId IdType="pubmed">35640925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabbani D, Yotis DM, Ferreira VH, Shalhoub S, Belga S, Tyagi V, et al. Immunogenicity, safety, and breakthrough severe acute respiratory syndrome coronavirus 2 infections after Coronavirus Disease 2019 vaccination in organ transplant recipients: a prospective multicenter Canadian study. Open Forum Infect Dis. 2023;10(5):ofad200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10199121</ArticleId><ArticleId IdType="pubmed">37213422</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolgavkar SH, Moller H, Woodward A. Principles of the epidemiological approach to QEP. IARC Sci Publ. 1999;131:61–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10505293</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanodja B, Ronicke S, Budde K, Jens A, Hammett C, Koch N, et al. Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients. J Clin Med. 2022;11(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9105533</ArticleId><ArticleId IdType="pubmed">35566691</ArticleId></ArticleIdList></Reference><Reference><Citation>Terbinafine is best treatment for fungal nail infection. BMJ. 1999;318(7190):B.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1115426</ArticleId><ArticleId IdType="pubmed">10205136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira VH, Ierullo M, Mavandadnejad F, Kurtesi A, Hu Q, Hardy WR, et al. Omicron BA.4/5 neutralization and t-cell responses in organ transplant recipients after booster messenger RNA vaccine: a multicenter cohort study. Clin Infect Dis. 2023;77(2):229–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">36975097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schietzel S, Anderegg M, Limacher A, Born A, Horn MP, Maurer B, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open. 2022;8(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814433</ArticleId><ArticleId IdType="pubmed">35115385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovd M, Asberg A, Munthe LA, Heldal K, Reisaeter AV, Vaage JT, et al. Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study. EClinicalMedicine. 2023;60: 102035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242148</ArticleId><ArticleId IdType="pubmed">37362086</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol. 2023;55(4):791–802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890430</ArticleId><ArticleId IdType="pubmed">36723829</ArticleId></ArticleIdList></Reference><Reference><Citation>Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6(7):2014–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639290</ArticleId><ArticleId IdType="pubmed">34852173</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechotta V, Mellinghoff SC, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022;12(5):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9152308</ArticleId><ArticleId IdType="pubmed">35641489</ArticleId></ArticleIdList></Reference><Reference><Citation>Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi SA, Bashash D. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. Int Immunopharmacol. 2022;110: 109046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273573</ArticleId><ArticleId IdType="pubmed">35843148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi I, Pratama S, Wiyono L, Tandaju JR, Wardhana IL, Winston K. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: systematic review and meta-analysis. Front Oncol. 2022;12: 951215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393790</ArticleId><ArticleId IdType="pubmed">36003763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6(24):6198–207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561400</ArticleId><ArticleId IdType="pubmed">36538342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. Vaccine. 2023;41(24):3636–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154542</ArticleId><ArticleId IdType="pubmed">37173268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai AS, Lee A, Tay RYK, Shapiro L, Thakkar A, Halmos B, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022;172:65–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163022</ArticleId><ArticleId IdType="pubmed">35753213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong IY, Vijenthira A, Betschel SD, Hicks LK, Cheung MC. COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis. Am J Hematol. 2022;97(4):E132–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011569</ArticleId><ArticleId IdType="pubmed">35007350</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinana JL, Martino R, Vazquez L, Lopez-Corral L, Perez A, Chorao P, et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transpl. 2023;58(5):567–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9974060</ArticleId><ArticleId IdType="pubmed">36854892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Honda A, Kurokawa M. COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2022;22(8):e691–707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8958822</ArticleId><ArticleId IdType="pubmed">35459624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu C, Schonbrunn A, Fischer D, Liu Y, Hocher JG, Weinerth J, et al. Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients. Front Immunol. 2023;14:1187880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10291065</ArticleId><ArticleId IdType="pubmed">37377957</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. 2022;4(11):e775-e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381025</ArticleId><ArticleId IdType="pubmed">35991760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):8562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058064</ArticleId><ArticleId IdType="pubmed">33879826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021;12(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7885108</ArticleId><ArticleId IdType="pubmed">33563817</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. PLoS ONE. 2021;16(5): e0250602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092779</ArticleId><ArticleId IdType="pubmed">33939733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, et al. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Front Immunol. 2021;12: 704773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242233</ArticleId><ArticleId IdType="pubmed">34220867</ArticleId></ArticleIdList></Reference><Reference><Citation>Frittoli M, Cassia M, Barassi A, Ciceri P, Galassi A, Conte F, et al. Efficacy and safety of COVID-19 vaccine in patients on renal replacement therapy. Vaccines (Basel). 2022;10(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504940</ArticleId><ArticleId IdType="pubmed">36146472</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroga B, Soler MJ, Ortiz A, Martinez Vaquera S, Jarava Mantecon CJ, Useche G, et al. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transpl. 2022;37(10):1868–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767866</ArticleId><ArticleId IdType="pubmed">34788858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transpl. 2020;35(12):2083–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716804</ArticleId><ArticleId IdType="pubmed">33275763</ArticleId></ArticleIdList></Reference><Reference><Citation>Affeldt P, Koehler FC, Brensing KA, Gies M, Platen E, Adam V, et al. Immune response to third and fourth COVID-19 vaccination in hemodialysis patients and kidney transplant recipients. Viruses. 2022;14(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785871</ArticleId><ArticleId IdType="pubmed">36560648</ArticleId></ArticleIdList></Reference><Reference><Citation>Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K. A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients. Ups J Med Sci. 2022;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9602199</ArticleId><ArticleId IdType="pubmed">36337280</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarhaus M, Duhanes M, Lesevic N, Matei B, Ramsauer B, Da Silva RR, et al. Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients. Scand J Immunol. 2022;95(5): e13152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115353</ArticleId><ArticleId IdType="pubmed">35244289</ArticleId></ArticleIdList></Reference><Reference><Citation>Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, et al. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int. 2022;101(2):390–402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628628</ArticleId><ArticleId IdType="pubmed">34856313</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdier JF, Boyer S, Chalmin F, Jeribi A, Egasse C, Maggi MF, et al. Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France. BMC Nephrol. 2022;23(1):189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116059</ArticleId><ArticleId IdType="pubmed">35585512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fucci A, Giacobbe S, Guerriero I, Suzumoto Y, D’Andrea EL, Scrima M, et al. The DiaCoVAb study in South Italy: immune response to SARS-CoV-2 vaccination in dialysis patients. Kidney Blood Press Res. 2022;47(7):467–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148885</ArticleId><ArticleId IdType="pubmed">35318291</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroga B, Soler MJ, Ortiz A, Gansevoort RT, Leyva A, Rojas J, et al. Long-term dynamic humoral response to SARS-CoV-2 mRNA vaccines in patients on peritoneal dialysis. Vaccines (Basel). 2022;10(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9609237</ArticleId><ArticleId IdType="pubmed">36298603</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilhack G, Monteforte R, Frommlet F, Reindl-Schwaighofer R, Strassl R, Vychytil A. Humoral response to mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients: Is boostering after six months adequate? Front Med (Lausanne). 2022;9: 905798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9263093</ArticleId><ArticleId IdType="pubmed">35814775</ArticleId></ArticleIdList></Reference><Reference><Citation>Berar-Yanay N, Freiman S, Shapira M, Saffoury A, Elemy A, Hamze M, et al. Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. J Clin Med. 2021;11(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745040</ArticleId><ArticleId IdType="pubmed">35011801</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwinkler L, Solagna CA, Messner J, Pirklbauer M, Rudnicki M, Mayer G, et al. Antibody response to mRNA vaccines against SARS-CoV-2 with chronic kidney disease, hemodialysis, and after kidney transplantation. J Clin Med. 2021;11(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745313</ArticleId><ArticleId IdType="pubmed">35011888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Mansouri F, Sio TT, Sullman MJM, et al. Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. Rev Med Virol. 2022;32(3): e2309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646697</ArticleId><ArticleId IdType="pubmed">34677889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, Haarhaus M, et al. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. J Nephrol. 2021;34(4):975–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164063</ArticleId><ArticleId IdType="pubmed">34050904</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun. 2022;13(1):5362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467419</ArticleId><ArticleId IdType="pubmed">36097029</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley HJ, Li NC, Aweh GN, Hsu CM, Weiner DE, Miskulin D, et al. SARS-CoV-2 vaccine effectiveness and breakthrough infections among patients receiving maintenance dialysis. Am J Kidney Dis. 2023;81(4):406–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711902</ArticleId><ArticleId IdType="pubmed">36462570</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191–204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8874732</ArticleId><ArticleId IdType="pubmed">35217850</ArticleId></ArticleIdList></Reference><Reference><Citation>Joudeh AI, Lutf AQ, Mahdi S, Tran G. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: a systematic review. Vaccine. 2023;41(26):3801–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201317</ArticleId><ArticleId IdType="pubmed">37244811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood A, Tran M, Murthy V, Gonzalez E. Immunogenicity and safety of SARS-CoV-2 vaccination in patients with rheumatic diseases: a systematic review and meta-analysis. J Clin Rheumatol. 2022;28(8):381–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35660717</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-Garcia A, Tseng LY, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011807</ArticleId><ArticleId IdType="pubmed">34807517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, et al. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis. 2023;82(2):292–300.</Citation><ArticleIdList><ArticleId IdType="pubmed">36109141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, van Dam KPJ, Steenhuis M, Stalman EW, Kummer LYL, van Kempen ZLE, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4(5):e338–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930018</ArticleId><ArticleId IdType="pubmed">35317410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorlykke KH, Orbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, et al. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatol. 2023;5(1):e36–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671616</ArticleId><ArticleId IdType="pubmed">36415604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SYS, Yee AM, Sim JJL, Lim CC. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology (Oxford). 2023;62(5):1757–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9620290</ArticleId><ArticleId IdType="pubmed">36271852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>